Epidermal growth factor receptor kinase domain mutations are rare in salivary gland carcinomas

British Journal of Cancer

Volumn 100, Issue 4, 2009, Pages 623-625

  Dahse, R ^a   Driemel, O ^b   Schwarz, S ^c   Dahse, J ^d   Kromeyer Hauschild, K ^e   Berndt, A ^e   Kosmehl, H ^a  

^a HELIOS KLINIKUM ERFURT   (Germany)

^b UNIVERSITY OF REGENSBURG   (Germany)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^d RUHR UNIVERSITY BOCHUM   (Germany)

^e FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Epidermal growth factor receptor; Mutation screening; Salivary gland carcinomas; Targeted therapy

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR KINASE;

ACINAR CELL CARCINOMA; ADENOID CYSTIC CARCINOMA; ADENOSQUAMOUS CARCINOMA; ADULT; ALLELE; ARTICLE; CANCER DIAGNOSIS; EXON; FEMALE; GENE DELETION; GENE MUTATION; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MYOEPITHELIOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SALIVARY GLAND CARCINOMA; SCREENING; SEQUENCE ANALYSIS;

AGED; COHORT STUDIES; DNA MUTATIONAL ANALYSIS; EXONS; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; PROTEIN STRUCTURE, TERTIARY; RECEPTOR, EPIDERMAL GROWTH FACTOR; SALIVARY GLAND NEOPLASMS;

EID: 60349131435     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604875     Document Type: Article

References (19)

1. Agulnik M, Cohen EW, Cohen RB, Chen EX, Vokes EE, Hotte SJ, Winquist E, Laurie S, Hayes DN, Dancey JE, Brown S, Pond GR, Lorimer I, Daneshmand M, Ho J, Tsao MS, Siu LL (2007) Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. J Clin Oncol 25: 3978-3984
2. Barnes L, Eveson W, Reichart P, Sidransky W (2005) Pathology and Genetics of Head and Neck Tumours. World Health Organization Classification of Tumours. IARC Press: Lyon, France, pp 210-242
3. Cohen EE, Kane MA, List MA, Brockstein BE, Mehrotra B, Huo D, Mauer AM, Pierce C, Dekker A, Vokes EE (2005) Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res 11: 8418-8424
4. Dahse R, Kosmehl H (2008) Detection of drug-sensitizing EGFR exon 19 deletion mutations in salivary gland carcinoma. Br J Cancer 99: 90-92
5. Eberhard DA, Johnson BE, Amler LC, Goddard AD, Heldens SL, Herbst RS, Ince WL, Janne PA, Januario T, Johnson DH, Klein P, Miller VA, Ostland MA, Ramies DA, Sebisanovic D, Stinson JA, Zhang YR, Seshagiri S, Hillan KJ (2005) Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 23: 5900-5909
6. Ettl T, Schwarz S, Kuhnel T, Stockmann P, Reichert TE, Driemel O (2008) [Prognostic value of immunohistochemistry in salivary gland cancer]. HNO 56: 231-238
7. Glisson BS, Blumenschein G, Francisco M, Erasmus J, Zinner R, Kies M (2005) Phase II trial of gefitinib in patients with incurable salivary gland cancer. J Clin Oncol 23: 16S-5532
8. Han SW, Kim HP, Jeon YK, Oh DY, Lee SH, Kim DW, Im SA, Chung DH, Heo DS, Bang YJ, Kim TY (2008) Mucoepidermoid carcinoma of lung: Potential target of EGFR-directed treatment. Lung Cancer 61(1): 30-34
9. Lee JW, Soung YH, Kim SY, Nam HK, Park WS, Nam SW, Kim MS, Sun DI, Lee YS, Jang JJ, Lee JY, Yoo NJ, Lee SH (2005) Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck. Clin Cancer Res 11: 2879-2882
10. Locati LD, Bossi P, Perrone F, Potepan P, Crippa F, Mariani L, Casieri P, Orsenigo M, Losa M, Bergamini C, Liberatoscioli C, Quattrone P, Calderone RG, Rinaldi G, Pilotti S, Licitra L (2008) Cetuximab in recurrent and/or metastatic salivary gland carcinomas: A phase II study. Oral Oncol (e-pub ahead of print 17 September 2008)
11. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139
12. Macarenco RS, Uphoff TS, Gilmer HF, Jenkins RB, Thibodeau SN, Lewis JE, Molina JR, Yang P, Aubry MC (2008) Salivary gland-type lung carcinomas: an EGFR immunohistochemical, molecular genetic, and mutational analysis study. Mod Pathol 21: 1168-1175
13. Milano A, Longo F, Basile M, Iaffaioli RV, Caponigro F (2007) Recent advances in the treatment of salivary gland cancers: emphasis on molecular targeted therapy. Oral Oncol 43: 729-734
14. Mitsudomi T, Yatabe Y (2007) Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci 98: 1817-1824
15. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500
16. Riely GJ, Pao W, Pham D, Li AR, Rizvi N, Venkatraman ES, Zakowski MF, Kris MG, Ladanyi M, Miller VA (2006a) Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res 12: 839-844
17. Riely GJ, Politi KA, Miller VA, Pao W (2006b) Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin Cancer Res 12: 7232-7241
18. Sequist LV, Martins RG, Spigel D, Grunberg SM, Spira A, Janne PA, Joshi VA, McCollum D, Evans TL, Muzikansky A, Kuhlmann GL, Han M, Goldberg JS, Settleman J, Iafrate AJ, Engelman JA, Haber DA, Johnson BE, Lynch TJ (2008) First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 26: 2442-2449
19. Tamura K, Okamoto I, Kashii T, Negoro S, Hirashima T, Kudoh S, Ichinose Y, Ebi N, Shibata K, Nishimura T, Katakami N, Sawa T, Shimizu E, Fukuoka J, Satoh T, Fukuoka M (2008) Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403). Br J Cancer 98: 907-914